CCN2/CTGF mRNA expression was higher in breast cancer, head and neck cancer, thyroid cancer, pancreatic cancer, glioma, endometrial cancer, ovarian cancer, renal cancer, compared to testis cancer and other cancer types (Figure 8B). This evidence concerns the gene CCN2 and ovarian carcinoma.